Case Report Open Access
Copyright ©The Author(s) 2003. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Mar 15, 2003; 9(3): 631-632
Published online Mar 15, 2003. doi: 10.3748/wjg.v9.i3.631
Successful rescuing a pregnant woman with severe hepatitis E infection and postpartum massive hemorrhage
Zhan-Sheng Jia, Yu-Mei Xie, Jun-Rong Di, Chang-Xing Huang, Xue-Fang Bai, Center of Diagnosis and Treatment for Infectious Diseases of PLA, Tangdu Hospital, Fourth Military Medical University, Xi’an 730038, Shaanxi Province
Guo-Wu Yin, Department of Obstetrics and Gynecology, Tangdu Hospital, Fourth Military Medical University, Xi’an 730038, Shaanxi Province
Wei-Pin Guo, Department of Intervention, Tangdu Hospital, Fourth Military Medical University, Xi’an 730038, Shaanxi Province
Correspondence to: Dr. Zhan-Sheng Jia, Center of Diagnosis and Treatment for Infectious Diseases of PLA, Tangdu Hospital, 1 Xinsi Road, Baqiao District, Xi’an 710038, Shaanxi Province, China. jiazsh@fmmu.edu.cn
Telephone: +86-29-3377742 Fax: +86-29-3537377
Received: October 30, 2002
Revised: November 13, 2002
Accepted: November 19, 2002
Published online: March 15, 2003

Abstract

AIM: To sum up the experience of the successful therapy for the severe hepatitis of pregnant woman with postpartum massive hemorrhage.

METHODS: The advanced therapeutic methods including the bilateral uterine artery embolism, hemodialysis and artificial liver support therapy were performed with comprehensive medical treatments and the course of the successful rescuing the patient was analyzed.

RESULTS: Through the hospitalization of about two mouths the patient and her neonatus had gotten the best of care in our department and pediatric department separately. Both of them were discharged in good condition.

CONCLUSION: The key points for a successful therapy of the pregnant woman with severe hepatitis are termination of the pregnancy and the control of their various complications. It was suggested that the proper combination of these measures of modern therapy would race against time for renewing of hepatic and renal functions.




INTRODUCTION

Hepatitis E infection is the most common cause of severe hepatitis in pregnancy, being seriously dangerous for both maternal and fetal life with a mortality rate of 58%, even up to 100% if a postpartum massive hemorrhage occurs[1-4]. A pregnant woman with severe hepatitis E infection complicated with postpartum massive hemorrhage and fulminant hepatic and acute renal failure is presented in this report. With the comprehensive medical treatments in an intensive care setting and three advanced therapeutic measures including bilateral uterine artery embolism, hemodialysis and artificial liver support therapy, a satisfactory outcome of both the mother and child was achieved.

CASE REPORT

A 24-year-old pregnant woman was admitted to our hospital in May 11th 2002 and presented with a 31-week pregnancy and an 11-day history of asthania, abdominal distention with deep jaundice. On examination she had a blood pressure of 20/12 kPa, peripheral and facial puffiness, icteric sclera and xanthochromia. The fetal heart rate was 140 beats/min. Laboratory findings showed a normal white blood cell count and a decreased platelet counts (76 × 109/L) with a hemoglobin level of 102 g/L. Liver function tests were obvious abnormal (albumin 25.9 g/L, bilirubin 579 μmol/L, alanine transaminase 158 IU/L). Prothrombin time activity (PTA) was 21.5%. The markers of hepatitis virus showed negative for hepatitis A, C and D, positive for anti-HB surface and anti-HE (IgM). So a diagnosis of fulminant hepatic failure of pregnancy (FHFP) with hepatitis E infection was made.

A further clinical course gave a risk signal for the maternal and fetal life. After admission, the gravid woman in the intensive care unit was treated by catharsis with lactulose in order to terminate the pregnancy. With the regular uterine contraction and colporrhagia that appeared as parturient signals, she was immediately sent to the childbearing ward for parturition. After the childbirth of a 1300 g-weight male baby who was sent to the pediatric care ward, the patient developed postpartum massive hemorrhage. Her blood pressure dropped to 10.7-6.67/6.67-4.0 kPa, at a minimum falling to 0/0 kPa. With the drug hemostasis, such as uterotonic, thromboplasin, and p-amino-merthyl beozoic acid, her colporrhagia could not be stopped. The total of her hemorrhage was about 3500 ml, and she was on the verge of death. Therefore, it was decided to perform the bilateral uterine artery embolism by the method of intervention. As a result, her colporrhagia was effectively controlled. At the same time fresh blood was transfused together with albumin, and her blood pressure rose up to 15.5/ 11.5 kPa with the normal vital signs.

After a dangerous delivery the patient underwent a clinical course of exacerbation with hepatic encephalopathy, hepatic renal syndrome, bacterial infection of puerperium and disseminated intravascular coagulation (DIC). The parturient presented fever (to 39.8 °C), oliguria ( < 400 ml/d) and confusion. The physical signs included severe edema of the whole body, intensive stasis of blood under subcutaneous layer of the abdominal wall and bilateral groin, and huge amount of hemorrhagic ascites. Laboratory study showed that the white blood cell count was 28.8 × 109/L, N 0.89, Hb 49 × 109/L, serum creatinine 583.3 μmol/L, blood urea nitrogen 24.2 μmol/L, blood NH3 164 μmol/L. The tests for DIC revealed thrombocytopenia (42 × 109/L), prolonged prothrombin time (PT 32.8 seconds, normal range from 11 to 14 seconds) and active partial thromboplastin time (APTT88.5 seconds, normal range from 25 to 36 seconds), and hypofibrinogenemia (0.23 g/L).

It was the key time to rescue her hepatic and renal function. The comprehensive medical treatments including diuresis, hemostasis (antifibrinnolytic agents and prothrombin complex) was used with antibiotics for controlling infection and a large number of albumin for improving hypoproteinemia, and in the meanwhile twice hemodialysis for getting rid of the toxic metabolite and the much abundance of her body water were performed. And so the renal and coagulative functions were effectively improved with the increase of her urine volume and the reduction of her whole body edema. However, the improvement of her hepatic function was not significant, total bilirubin remaining at 468 μmol/L. Therefore, it was decided that the artificial liver support therapy, an advanced therapeutic approach, was carried out and then the patient got better in her liver function and clinical syndromes with a good appetite. Through the hospitalization of about two mouths the patient and her neonatus had gotten the best of care in our department and pediatric department separately. Both of them were discharged in good condition.

DISCUSSION

Viral hepatitis during pregnancy is common in China[5-13]. It is one of the most dangerous conditions with a high mortality both for the mother and her fetus, particularly when fulminant hepatic failure occurred[2,3]. Severe hepatitis is the main cause of FHFP in terms of the trimester of gestation[4]. The pregnant woman with severe hepatitis presents frequently hypodynamia, deep jaundice, coma, hypoproteinemia and sometime acute renal failure[5]. The patient in this report had a 31-week pregnancy developed severe hepatic dysfunction with deep jaundice (TB 579.9 μmol/L, PTA 21.5%), and a positive anti-HE-IgM in her serum, therefore severe hepatitis of pregnancy with HEV infection was diagnosed. It was reported that there were many viruses causing severe hepatitis of pregnancy, but HEV and HBV were frequent, especially HEV infection. The mortality rate was highest (56%) among HEV infected FHF cases during the third trimester of pregnancy[4,14].

Intensive care facilities and an early diagnosis are essential for the management of pregnant patient with severe liver disease[1,2,14]. The key points for a successful therapy of them are termination of the pregnancy on the proper time and the control of their various complications. It was reported that the severe hepatitis of pregnant woman was with a high mortality rate, even up to 100% if a postpartum massive hemorrhage and hepatic renal syndrome occur. In this case she presented the very severe hepatic dysfunction and coagulative dysfunctions, and complicated with postpartum massive hemorrhage, bacterial infection, hepatic encephalopathy and hepatic renal syndrome meanwhile or continuously. Therefore the treatments of her were usually very difficult and contradictory.

We considered that the key points of the successful rescuing the patient were on the proper time to adopt three important therapeutic measures. The first was to perform decisively on proper time the bilateral uterine artery embolism by the intervention that is an advanced method with a smaller damage in comparison of the complete hysterectomy and effectively stopped the postpartum massive hemorrhage. The second was to use twice hemodialysis by which removed the toxic metabolite and the abundance of water and the proper comprehensive medical treatments for the improvement of her renal and coagulative function. The third was to carry out in time the artificial liver support therapy that provides a temporary liver support and promotes the spontaneous liver regeneration in the patient with the remove of toxic metabolic products and the decrease of total bilirubin[15-18]. It was suggested that the proper combination of these measures of modern therapy would race against time for renewing of hepatic and renal functions, and therefore a better outcome of treatment was anticipated.

References
1.  Jaiswal SP, Jain AK, Naik G, Soni N, Chitnis DS. Viral hepatitis during pregnancy. Int J Gynaecol Obstet. 2001;72:103-108.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 96]  [Cited by in F6Publishing: 99]  [Article Influence: 4.3]  [Reference Citation Analysis (0)]
2.  Tank PD, Nadanwar YS, Mayadeo NM. Outcome of pregnancy with severe liver disease. Int J Gynaecol Obstet. 2002;76:27-31.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 22]  [Cited by in F6Publishing: 22]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
3.  Yang W, Shen Z, Peng G, Chen Y, Jiang S, Kang S, Wu J. Acute fatty liver of pregnancy: diagnosis and management of 8 cases. Chin Med J (Engl). 2000;113:540-543.  [PubMed]  [DOI]  [Cited in This Article: ]
4.  Hussaini SH, Skidmore SJ, Richardson P, Sherratt LM, Cooper BT, O'Grady JG. Severe hepatitis E infection during pregnancy. J Viral Hepat. 1997;4:51-54.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 93]  [Cited by in F6Publishing: 107]  [Article Influence: 4.0]  [Reference Citation Analysis (0)]
5.  Yan J, Chen LL, Luo YH, Mao YF, He M. High frequencies of HGV and TTV infections in blood donors in Hangzhou. World J Gastroenterol. 2001;7:637-641.  [PubMed]  [DOI]  [Cited in This Article: ]
6.  Yan J, Ma JY, Pan BR, Ma LS. Study on hepatitis B virus in China. Shijie Huaren Xiaohua Zazhi. 2001;9:611-616.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Yuan JM, Govindarajan S, Gao YT, Ross RK, Yu MC. Prospective evaluation of infection with hepatitis G virus in relation to hepatocellular carcinoma in Shanghai, China. J Infect Dis. 2000;182:1300-1303.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 7]  [Cited by in F6Publishing: 7]  [Article Influence: 0.3]  [Reference Citation Analysis (0)]
8.  Wen YM. Laboratory diagnosis of viral hepatitis in China: the present and the future. Clin Chem Lab Med. 2001;39:1183-1189.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Wang XZ, Jiang XR, Chen XC, Chen ZX, Li D, Lin JY, Tao QM. Seek protein which can interact with hepatitis B virus X protein from human liver cDNA library by yeast two-hybrid system. World J Gastroenterol. 2002;8:95-98.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Wei J, Wang YQ, Lu ZM, Li GD, Wang Y, Zhang ZC. Detection of anti-preS1 antibodies for recovery of hepatitis B patients by immunoassay. World J Gastroenterol. 2002;8:276-281.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Zhang Z, Wang J, Jiang L. [Epidemiological characteristics and risk factors of hepatitis E in Taiyuan]. Zhonghua Yufang Yixue Zazhi. 1997;31:144-146.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Wu C, Tao Q. Comparison between homologies of E2/NS1 gene from genotype III Chinese isolates of hepatitis C virus and that from reported isolates. Chin Med J (Engl). 1998;111:807-809.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Guo XC, Wu YQ. A review: progress of prevention and control on viral hepatitis in China. Biomed Environ Sci. 1999;12:227-232.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Luo KX, Zhang L, Wang SS, Nie J, Yang SC, Liu DX, Liang WF, He HT, Lu Q. An outbreak of enterically transmitted non-A, non-E viral hepatitis. J Viral Hepat. 1999;6:59-64.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 16]  [Article Influence: 0.6]  [Reference Citation Analysis (0)]
15.  Hamid SS, Jafri SM, Khan H, Shah H, Abbas Z, Fields H. Fulminant hepatic failure in pregnant women: acute fatty liver or acute viral hepatitis. J Hepatol. 1996;25:20-27.  [PubMed]  [DOI]  [Cited in This Article: ]
16.  Strain AJ, Neuberger JM. A bioartificial liver--state of the art. Science. 2002;295:1005-1009.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 220]  [Cited by in F6Publishing: 206]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
17.  Nyberg SL, Hay EJ, Ramin KD, Rosen CB. Successful pregnancy after porcine bioartificial liver treatment and liver transplantation for fulminant hepatic failure. Liver Transpl. 2002;8:169-170.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 3]  [Cited by in F6Publishing: 4]  [Article Influence: 0.2]  [Reference Citation Analysis (0)]
18.  Morsiani E, Pazzi P, Puviani AC, Brogli M, Valieri L, Gorini P, Scoletta P, Marangoni E, Ragazzi R, Azzena G. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs. 2002;25:192-202.  [PubMed]  [DOI]  [Cited in This Article: ]